Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.

Green CL, Tawana K, Hills RK, Bödör C, Fitzgibbon J, Inglott S, Ancliff P, Burnett AK, Linch DC, Gale RE.

Br J Haematol. 2013 Jun;161(5):701-5. doi: 10.1111/bjh.12317. Epub 2013 Apr 5.

PMID:
23560626
2.

CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.

Grossmann V, Haferlach C, Nadarajah N, Fasan A, Weissmann S, Roller A, Eder C, Stopp E, Kern W, Haferlach T, Kohlmann A, Schnittger S.

Br J Haematol. 2013 Jun;161(5):649-58. doi: 10.1111/bjh.12297. Epub 2013 Mar 25.

PMID:
23521373
3.

GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.

Hou HA, Lin YC, Kuo YY, Chou WC, Lin CC, Liu CY, Chen CY, Lin LI, Tseng MH, Huang CF, Chiang YC, Liu MC, Liu CW, Tang JL, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF.

Ann Hematol. 2015 Feb;94(2):211-21. doi: 10.1007/s00277-014-2208-8. Epub 2014 Sep 21.

PMID:
25241285
4.

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.

Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B, Sturm J, Benthaus T, Herold T, Yaghmaie M, Dörge P, Hopfner KP, Hauser A, Graf A, Krebs S, Blum H, Kakadia PM, Schneider S, Hoster E, Schneider F, Stanulla M, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK.

Blood. 2012 Jul 12;120(2):395-403. doi: 10.1182/blood-2012-01-403220. Epub 2012 May 30.

5.

Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia.

Shiba N, Funato M, Ohki K, Park MJ, Mizushima Y, Adachi S, Kobayashi M, Kinoshita A, Sotomatsu M, Arakawa H, Tawa A, Horibe K, Tsukimoto I, Hayashi Y.

Br J Haematol. 2014 Jan;164(1):142-5. doi: 10.1111/bjh.12559. Epub 2013 Sep 14. No abstract available.

PMID:
24033149
6.

GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.

Fasan A, Eder C, Haferlach C, Grossmann V, Kohlmann A, Dicker F, Kern W, Haferlach T, Schnittger S.

Leukemia. 2013 Feb;27(2):482-5. doi: 10.1038/leu.2012.174. Epub 2012 Jul 3. No abstract available.

PMID:
22814295
7.

ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia.

Damm F, Wagner K, Görlich K, Morgan M, Thol F, Yun H, Delwel R, Valk PJ, Löwenberg B, Heuser M, Ganser A, Krauter J.

Br J Haematol. 2012 Jul;158(2):208-15. doi: 10.1111/j.1365-2141.2012.09144.x. Epub 2012 May 9.

PMID:
22568493
8.

Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.

Fos J, Pabst T, Petkovic V, Ratschiller D, Mueller BU.

Blood. 2011 May 5;117(18):4881-4. doi: 10.1182/blood-2010-11-320747. Epub 2011 Mar 9.

9.

Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.

Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU.

J Clin Oncol. 2008 Nov 1;26(31):5088-93. doi: 10.1200/JCO.2008.16.5563. Epub 2008 Sep 2.

PMID:
18768433
10.

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander SK, Spiekermann K.

J Clin Oncol. 2010 Feb 1;28(4):570-7. doi: 10.1200/JCO.2008.21.6010. Epub 2009 Dec 28.

PMID:
20038735
11.

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.

Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE.

J Clin Oncol. 2010 Jun 1;28(16):2739-47. doi: 10.1200/JCO.2009.26.2501. Epub 2010 May 3.

PMID:
20439648
12.

CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.

Awad MM, Aladle DA, Abousamra NK, Elghannam DM, Fawzy IM.

Hematology. 2013 Mar;18(2):61-8. doi: 10.1179/1607845412Y.0000000032. Epub 2012 Sep 14.

PMID:
22990006
13.

Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.

Ahn JS, Kim JY, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD.

Ann Hematol. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7. Epub 2015 Nov 4. Erratum in: Ann Hematol. 2016 Jan;95(2):363.

PMID:
26537612
14.

Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival.

Bödör C, Renneville A, Smith M, Charazac A, Iqbal S, Etancelin P, Cavenagh J, Barnett MJ, Kramarzová K, Krishnan B, Matolcsy A, Preudhomme C, Fitzgibbon J, Owen C.

Haematologica. 2012 Jun;97(6):890-4. doi: 10.3324/haematol.2011.054361. Epub 2012 Jan 22.

15.

Risk assessment in patients with acute myeloid leukemia and a normal karyotype.

Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.

Clin Cancer Res. 2005 Feb 15;11(4):1416-24. Erratum in: Clin Cancer Res. 2005 Aug 1;11(15):5659.

16.

Poor prognosis in familial acute myeloid leukaemia with combined biallelic CEBPA mutations and downstream events affecting the ATM, FLT3 and CDX2 genes.

Carmichael CL, Wilkins EJ, Bengtsson H, Horwitz MS, Speed TP, Vincent PC, Young G, Hahn CN, Escher R, Scott HS.

Br J Haematol. 2010 Aug;150(3):382-5. doi: 10.1111/j.1365-2141.2010.08204.x. Epub 2010 Apr 29. No abstract available.

PMID:
20456351
17.

Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.

Szankasi P, Ho AK, Bahler DW, Efimova O, Kelley TW.

Leuk Res. 2011 Feb;35(2):200-7. doi: 10.1016/j.leukres.2010.09.018. Epub 2010 Oct 20.

PMID:
20970189
18.

Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts.

Tominaga-Sato S, Tsushima H, Ando K, Itonaga H, Imaizumi Y, Imanishi D, Iwanaga M, Taguchi J, Fukushima T, Yoshida S, Hata T, Moriuchi Y, Kuriyama K, Mano H, Tomonaga M, Miyazaki Y.

Int J Hematol. 2011 Jul;94(1):81-9. doi: 10.1007/s12185-011-0883-y. Epub 2011 Jun 16. Erratum in: Int J Hematol. 2012 Aug;96(2):291-2.

PMID:
21674360
19.

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.

Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K.

J Clin Oncol. 2004 Feb 15;22(4):624-33. Epub 2004 Jan 15.

PMID:
14726504
20.

Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.

Pabst T, Eyholzer M, Fos J, Mueller BU.

Br J Cancer. 2009 Apr 21;100(8):1343-6. doi: 10.1038/sj.bjc.6604977. Epub 2009 Mar 10.

Supplemental Content

Support Center